Inogen Inc (INGN)
NASDAQ:INGN
Want to see INGN full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.15Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call reflects a company in transition: solid top-line growth driven by international expansion, strong unit volume gains, new product launches with encouraging early clinical and commercial signals, and a healthy balance sheet. Offsetting these positives are meaningful near-term headwinds in the U.S. market (declining direct and rental sales), higher operating losses due to accelerated R&D and commercial investments, and reliance on a FX tailwind. Management reaffirmed full-year guidance and expects EBITDA improvement, but several financial metrics remain under pressure in the near term.Company Guidance
Revenue Growth and Beat
Total revenue of $85.1M for Q1 2026, up 3.4% year-over-year and above company expectations; total sales revenue increased 5.7% driven by international POC growth and favorable FX.
Unit Volume Expansion
Unit volumes grew 14% year-over-year, indicating strong demand and execution on device placements despite channel shifts in the U.S.
International Outperformance
International revenue of $37.7M, up 18% year-over-year; growth driven by deeper HME relationships, international tenders and expansion into Eastern Europe, Latin America and Asia Pacific.
Gross Margin Improvement
Adjusted gross margin increased to 44.7%, up 30 basis points versus prior year (from 44.4%), aided by cost improvements.
Product Launches and Clinical Momentum
Launched Aurora CPAP mask family in the U.S. with a positive 90-day in-home study showing patient preference (particularly for the full face mask); launched Rove 6 POC in Brazil; Simeox reimbursement trial (IMPACTS-200) began patient enrollment. Management expects Aurora revenue to be back-half weighted.
POC Product Differentiation
Rove 4 and Rove 6 POCs positioned with an 8-year useful life (vs. 5 years for competitors), best-in-class serviceability and growing outcomes data to support premium positioning.
Strong Liquidity and Capital Actions
Ended the quarter with $111.5M in cash, cash equivalents, marketable securities and restricted cash and zero debt; initiated share repurchase activity (≈298k shares for ~$1.9M).
Reaffirmed Guidance and Positive Full-Year Outlook
Reaffirmed 2026 revenue guidance of $366M–$373M (~6% growth at midpoint) and Q2 revenue guidance of $94M–$97M (~3.5% growth at midpoint); company expects adjusted EBITDA growth for the full year and seasonal Q2/Q3 strength.
INGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $7.19 | $7.02 | -2.36% |
Feb 24, 2026 | $5.84 | $6.01 | +2.91% |
Nov 05, 2025 | $8.06 | $7.39 | -8.31% |
Aug 07, 2025 | $5.87 | $6.48 | +10.39% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inogen Inc (INGN) report earnings?
Inogen Inc (INGN) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Inogen Inc (INGN) earnings time?
Inogen Inc (INGN) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INGN EPS forecast?
INGN EPS forecast for the fiscal quarter 2026 (Q2) is -0.17.